Tesaro: Losing It’s Edge?
August 18, 2017 at 16:39 PM EDT
U.S. regulators expanded use of AstraZeneca’s ovarian cancer drug Lynparza. What does that mean for rival Tesaro?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.